Iterum (NASDAQ: ITRM) Shares Plunge Following Release of Favorable REASSURE Clinical Trial Data
Iterum Therapeutics (NASDAQ: ITRM) stock plummeted almost 12% on Tuesday following the disclosure of positive topline outcomes from the Phase […]
ITRM shares
